Royalty Report: Drugs, Nutraceutical – Collection: 4354


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Nutraceutical

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 4354

License Grant
Licensor shall grant an exclusive, worldwide License to the Licensee, to all business assets and properties owned or utilized by Licensor as used in its regular coarse of business including but not limited to Licensor's distributor organization, rights, intellectual property including websites, URLs, trademarks, and trade names associated with the True2Life brand and product lines, any purchased or not purchased product inventory, as well as other assets and rights to be able to carry on the business as if Licensor was still running the business.
License Property
Licensor is an established corporation in the marketing and sale of products related to dietary supplement products and has developed a distributor organization of independent authorized agents for the sale of its products, including the True Boost and other 'True·• product brands, and the True2Life product lines.
Field of Use
Licensee wishes to license the rights to sell Licensor's products and use Licensor's distributor organization and Licensor wishes to sell and/or transfer, among other things, its distributor organization and the True2Life product line(s) and this Agreement is to witness the following.

IPSCIO Record ID: 7003

License Grant
The Licensor will grant to Licensee a perpetual, exclusive, worldwide license under patents and associated know-how and other intellectual property rights to develop, manufacture and commercialize probiotics for use as dietary supplements for human consumption or human use over-the-counter without a prescription or otherwise in the vitamins, minerals and supplements market (including foods or beverages marketed as supplements).

The Licensor hereby grants to Licensee, and Licensee hereby accepts, an exclusive, worldwide, license under the Licensed Patents to research, develop, improve, produce, manufacture, have manufactured, market, promote, offer to sell, sell, use, import, distribute and commercialize Probiotics and Products and otherwise exploit the Licensed Patents, in each case, for use in the Licensed Field of Use (the Patent License).

The Licensor grants to Licensee, an exclusive, worldwide License to use the Licensed Trademarks on any Product for use in the Field of Use including the use of BC30.

The Licensor grants an exclusive, worldwide License under the Licensed Copyrights.

License Property
The Licensor transferred certain inventory, receivables and intellectual property and certain liabilities relating to probiotic brands Sustenex and Digestive Advantage.
Field of Use
The rights granted apply for the use as dietary supplements for human consumption or human use over-the-counter without a prescription or otherwise in the vitamins, minerals and supplements market.

In connection Asset Purchase, Licensee wishes to obtain an exclusive, Worldwide License to certain Intellectual Property Rights including all Patents Controlled by the Licensor including all Patents that claim or otherwise cover, any Probiotic or Product, or the research, development, manufacture, use or commercialization thereof.

IPSCIO Record ID: 27700

License Grant
Licensor closed on the previously announced planned strategic sale of the ongoing business and assets of its BluScience consumer product line of dietary supplements to the licensee.
License Property
NSI of Canada has purchased all of the assets, rights and title of CDX in and to the products containing pterostilbene formerly marketed by CDX under the brand, “BluScience” including, but not limited to the products under the names, “HeartBlu”, “MemoryBlu”, “EternalBlu”, “TrimBlu” and “Blu2Go” (the “BluScience Products”) including the trademarks related to the “BluScience Products (“Trademarks”).

BluScience is a line of dietary supplement products which is directed toward providing a specific health benefit such as anti-aging, heart health, focus and energy and weight management containing our proprietary ingredients to various retail distribution channels.

Licensor will continue to generate revenue related to BluScience through both a royalty on future net sales of BluScience products as well as a supply agreement with licensee for its patented pTeroPure[R] pterostilbene, which will continue to be the key active ingredientin the BluScience product line. Licensor retained all rights and ownership to its pTeroPure pterostilbene.
The royalty extends to include the trademarks associated with the Product Line.

Field of Use
The Product Line includes the manufacture, distribution, marketing and sale of the products containing pterostilbene marketed by the licensor under the brand, “BluScience”, including, but not limited to the products under the names, “HeartBlu”, “MemoryBlu”, “EternalBlu”, “TrimBlu” and “Blū2Go”.  The sale does not include the pTeroPure brand (pterostilbene) and all related assets and intellectual property associated with such brand.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.